Novel therapeutic agents in Waldenström's macroglobulinemia

Clinical Lymphoma and Myeloma

Volumn 9, Issue 1, 2009, Pages 84-86

  Ghobrial, Irene ^a   Leleu, Xavier ^a   Azab, Abdel Kareem ^a   Runnels, Judith ^a   Jia, Xiaoying ^a   Ngo, Hai ^a   Melhem, Molly ^a   Azab, Feda ^a   Sacco, Antonio ^a   Quang, Phong ^a   Burwick, Nicholas ^a   Moreau, Anne Sophie ^a   Husu, Emanuel ^a   Farag, Mena ^a   Roccaro, Aldo ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Akt; Bortezomib; Everolimus; Perifosine; Waldenstr m

Indexed keywords

BORTEZOMIB; CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EVEROLIMUS; FLUDARABINE; HISTONE DEACETYLASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; PERIFOSINE; PHOSPHATIDYLINOSITOL 3 KINASE; PREDNISONE; PROTEIN KINASE B; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR;

ANEMIA; ARTHRITIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CYTOTOXICITY; DIARRHEA; DRUG DOSE REDUCTION; DRUG POTENTIATION; DRUG WITHDRAWAL; FATIGUE; HUMAN; HYPERGLYCEMIA; HYPONATREMIA; LEUKOPENIA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAIL DISEASE; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PNEUMONIA; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA; TREATMENT DURATION; VIRUS INFECTION; WALDENSTROEM MACROGLOBULINEMIA; REVIEW;

ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; HUMANS; WALDENSTROM MACROGLOBULINEMIA;

EID: 67649528659     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2009.n.022     Document Type: Article

References (11)

1. Ghobrial IM, Gertz MA, Fonseca R. Waldenstrom macroglobulinaemia. Lancet Oncol 2003; 4:679-85.
2. Dimopoulos MA, Kyle RA, Anagnostopoulos A, et al. Diagnosis and management of Waldenstrom's macroglobulinemia. J Clin Oncol 2005; 23:1564-77.
3. Treon SP, Dimopoulos M, Kyle RA. Defining Waldenstrom's macroglobulinemia. Semin Oncol 2003; 30:107-9.
4. Treon SP, Gertz MA, Dimopoulos M, et al. Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia. Blood 2006; 107:3442-6.
5. Vijay A, Gertz MA. Waldenstrom Macroglobulinemia. Blood 2007; 109:5096-103.
6. Moreau AS, Jia X, Ngo HT, et al. Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia. Blood 2007; 109:4964-72.
7. Roccaro AM, Leleu X, Sacco A, et al. Dual targeting of the proteasome regulates survival and homing in Waldenstrom's Macroglobulinemia. Blood 2008; 111:4752-63.
8. Hideshima T, Catley L, Yasui H, et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 2006; 107:4053-62.
9. Leleu X, Jia, X, Moreau, AS, et al. Perifosine, an oral bioactive novel Akt inhibitor, induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia. Blood 2006; 108:(Abstract 2488).
10. Leleu X, Jia X, Runnels J, et al. The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia. Blood 2007; 110:4417-26.
11. Leleu X, Eeckhoute J, Jia X, et al. Targeting NF-{kappa}B in Waldenstrom macroglobulinemia. Blood 2008; 111:5068-77.